Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 12, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $74.
The analyst noted that the company has shown progress in its pipeline. It is advancing its Barzolvolimab program, focusing on treating chronic spontaneous urticaria. The Phase 3 trials for this study are expected to finish enrollment in summer 2026. Moreover, the recent Phase 2 study showed promising results with many patients achieving complete responses and good disease control. Slutsky noted that the company has managed its cash burn efficiently and has a clear strategy, which justifies the Buy rating.
A closeup of a scientist conducting research in a clinical lab setting.
Celldex Therapeutics, Inc. is a clinical-stage biotech company focused on developing antibody-based therapies. The company targets mast cell-related diseases, including severe inflammatory and allergic conditions.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
